Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms

A tissue microarray and quantitative RT-PCR study

Evgeny Yakirevich, David J. Morris, Rosemarie Tavares, Patricia A. Meitner, Mirna Lechpammer, Lelia Noble, Angela F. De Rodriguez, Celso E. Gomez-Sanchez, Li J. Wang, Edmond Sabo, Ronald A. Delellis, Murray B. Resnick

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The kidney is an important target for mineralocorticoids. Aldosterone, the major endogenously secreted mineralocorticoid, acts by binding to mineralocorticoid receptor (MR) in the distal renal tubule. The enzyme 11β-hydroxysteroid dehydrogenase type II (11β-HSD2) prevents the binding of glucocorticoids to the MR by inactivating cortisol to cortisone. Our goal was to determine whether MR and 11β-HSD2 expression could be used to characterize the major types of renal cell neoplasms. Using immunohistochemistry we analyzed tissue microarray specimens from 132 patients with renal cell neoplasms, stratified into 84 clear cell renal cell carcinomas (CRCC), including 9 cases clear cell carcinoma with predominantly granular cytoplasm; 14 papillary RCC (PRCC); 20 chromophobe RCC (CHRCC); and 14 oncocytomas (OCs). MR and 11β-HSD2 expression were also quantitated by real-time reverse transcription-polymerase chain reaction. Expression of both MR and 11-βHSD2 was detected in the distal nephrons of normal kidneys. The CHRCC group stained for 11-βHSD2 in a membranous and cytoplasmic pattern whereas diffuse cytoplasmic reactivity was seen in OCs. MR and 11β-HSD2 were coexpressed in most of CHRCC (90% and 95%) and oncocytomas (93% and 100%). No MR staining was detected in CRCC, including clear cell carcinoma with predominantly granular cytoplasm, or in PRCC. Only 2 cases of CRCC (2.6%) showed focal positivity for 11β-HSD2, whereas all PRCCs were negative. CHRCC and OC demonstrated significantly higher levels of MR and 11β-HSD2 expression than CRCC and PRCC by real-time polymerase chain reaction. Moreover, CHRCC showed higher expression of MR and 11β-HSD2, as compared with OC. Our study indicates MR and 11β-HSD2 are both sensitive and specific markers of the distal nephron and its related neoplasms (CHRCC and OC). Additionally, the staining pattern and the level of MR and 11β-HSD2 expression seems to be useful in the distinction of CHRCC from OC. MR and 11β-HSD2 should be considered in the immunohistochemical panel to more accurately subtype renal cell tumors.

Original languageEnglish (US)
Pages (from-to)874-883
Number of pages10
JournalAmerican Journal of Surgical Pathology
Volume32
Issue number6
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

11-beta-Hydroxysteroid Dehydrogenases
Mineralocorticoid Receptors
Kidney Neoplasms
Oxyphilic Adenoma
Polymerase Chain Reaction
Renal Cell Carcinoma
Mineralocorticoids
Nephrons
Kidney
Cytoplasm
Distal Kidney Tubule
Staining and Labeling
Carcinoma
Cortisone
Aldosterone
Glucocorticoids
Reverse Transcription
Hydrocortisone
Real-Time Polymerase Chain Reaction

Keywords

  • 11b-hydroxysteroid dehydrogenase type II
  • Chromophobe carcinoma
  • Mineralocorticoid receptor
  • Oncocytoma
  • Renal cell neoplasms

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery
  • Medicine(all)

Cite this

Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms : A tissue microarray and quantitative RT-PCR study. / Yakirevich, Evgeny; Morris, David J.; Tavares, Rosemarie; Meitner, Patricia A.; Lechpammer, Mirna; Noble, Lelia; De Rodriguez, Angela F.; Gomez-Sanchez, Celso E.; Wang, Li J.; Sabo, Edmond; Delellis, Ronald A.; Resnick, Murray B.

In: American Journal of Surgical Pathology, Vol. 32, No. 6, 06.2008, p. 874-883.

Research output: Contribution to journalArticle

Yakirevich, E, Morris, DJ, Tavares, R, Meitner, PA, Lechpammer, M, Noble, L, De Rodriguez, AF, Gomez-Sanchez, CE, Wang, LJ, Sabo, E, Delellis, RA & Resnick, MB 2008, 'Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: A tissue microarray and quantitative RT-PCR study', American Journal of Surgical Pathology, vol. 32, no. 6, pp. 874-883. https://doi.org/10.1097/PAS.0b013e31815f2362
Yakirevich, Evgeny ; Morris, David J. ; Tavares, Rosemarie ; Meitner, Patricia A. ; Lechpammer, Mirna ; Noble, Lelia ; De Rodriguez, Angela F. ; Gomez-Sanchez, Celso E. ; Wang, Li J. ; Sabo, Edmond ; Delellis, Ronald A. ; Resnick, Murray B. / Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms : A tissue microarray and quantitative RT-PCR study. In: American Journal of Surgical Pathology. 2008 ; Vol. 32, No. 6. pp. 874-883.
@article{542d4dba3b9b4f0c8a9e787fdfdde3c9,
title = "Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: A tissue microarray and quantitative RT-PCR study",
abstract = "The kidney is an important target for mineralocorticoids. Aldosterone, the major endogenously secreted mineralocorticoid, acts by binding to mineralocorticoid receptor (MR) in the distal renal tubule. The enzyme 11β-hydroxysteroid dehydrogenase type II (11β-HSD2) prevents the binding of glucocorticoids to the MR by inactivating cortisol to cortisone. Our goal was to determine whether MR and 11β-HSD2 expression could be used to characterize the major types of renal cell neoplasms. Using immunohistochemistry we analyzed tissue microarray specimens from 132 patients with renal cell neoplasms, stratified into 84 clear cell renal cell carcinomas (CRCC), including 9 cases clear cell carcinoma with predominantly granular cytoplasm; 14 papillary RCC (PRCC); 20 chromophobe RCC (CHRCC); and 14 oncocytomas (OCs). MR and 11β-HSD2 expression were also quantitated by real-time reverse transcription-polymerase chain reaction. Expression of both MR and 11-βHSD2 was detected in the distal nephrons of normal kidneys. The CHRCC group stained for 11-βHSD2 in a membranous and cytoplasmic pattern whereas diffuse cytoplasmic reactivity was seen in OCs. MR and 11β-HSD2 were coexpressed in most of CHRCC (90{\%} and 95{\%}) and oncocytomas (93{\%} and 100{\%}). No MR staining was detected in CRCC, including clear cell carcinoma with predominantly granular cytoplasm, or in PRCC. Only 2 cases of CRCC (2.6{\%}) showed focal positivity for 11β-HSD2, whereas all PRCCs were negative. CHRCC and OC demonstrated significantly higher levels of MR and 11β-HSD2 expression than CRCC and PRCC by real-time polymerase chain reaction. Moreover, CHRCC showed higher expression of MR and 11β-HSD2, as compared with OC. Our study indicates MR and 11β-HSD2 are both sensitive and specific markers of the distal nephron and its related neoplasms (CHRCC and OC). Additionally, the staining pattern and the level of MR and 11β-HSD2 expression seems to be useful in the distinction of CHRCC from OC. MR and 11β-HSD2 should be considered in the immunohistochemical panel to more accurately subtype renal cell tumors.",
keywords = "11b-hydroxysteroid dehydrogenase type II, Chromophobe carcinoma, Mineralocorticoid receptor, Oncocytoma, Renal cell neoplasms",
author = "Evgeny Yakirevich and Morris, {David J.} and Rosemarie Tavares and Meitner, {Patricia A.} and Mirna Lechpammer and Lelia Noble and {De Rodriguez}, {Angela F.} and Gomez-Sanchez, {Celso E.} and Wang, {Li J.} and Edmond Sabo and Delellis, {Ronald A.} and Resnick, {Murray B.}",
year = "2008",
month = "6",
doi = "10.1097/PAS.0b013e31815f2362",
language = "English (US)",
volume = "32",
pages = "874--883",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms

T2 - A tissue microarray and quantitative RT-PCR study

AU - Yakirevich, Evgeny

AU - Morris, David J.

AU - Tavares, Rosemarie

AU - Meitner, Patricia A.

AU - Lechpammer, Mirna

AU - Noble, Lelia

AU - De Rodriguez, Angela F.

AU - Gomez-Sanchez, Celso E.

AU - Wang, Li J.

AU - Sabo, Edmond

AU - Delellis, Ronald A.

AU - Resnick, Murray B.

PY - 2008/6

Y1 - 2008/6

N2 - The kidney is an important target for mineralocorticoids. Aldosterone, the major endogenously secreted mineralocorticoid, acts by binding to mineralocorticoid receptor (MR) in the distal renal tubule. The enzyme 11β-hydroxysteroid dehydrogenase type II (11β-HSD2) prevents the binding of glucocorticoids to the MR by inactivating cortisol to cortisone. Our goal was to determine whether MR and 11β-HSD2 expression could be used to characterize the major types of renal cell neoplasms. Using immunohistochemistry we analyzed tissue microarray specimens from 132 patients with renal cell neoplasms, stratified into 84 clear cell renal cell carcinomas (CRCC), including 9 cases clear cell carcinoma with predominantly granular cytoplasm; 14 papillary RCC (PRCC); 20 chromophobe RCC (CHRCC); and 14 oncocytomas (OCs). MR and 11β-HSD2 expression were also quantitated by real-time reverse transcription-polymerase chain reaction. Expression of both MR and 11-βHSD2 was detected in the distal nephrons of normal kidneys. The CHRCC group stained for 11-βHSD2 in a membranous and cytoplasmic pattern whereas diffuse cytoplasmic reactivity was seen in OCs. MR and 11β-HSD2 were coexpressed in most of CHRCC (90% and 95%) and oncocytomas (93% and 100%). No MR staining was detected in CRCC, including clear cell carcinoma with predominantly granular cytoplasm, or in PRCC. Only 2 cases of CRCC (2.6%) showed focal positivity for 11β-HSD2, whereas all PRCCs were negative. CHRCC and OC demonstrated significantly higher levels of MR and 11β-HSD2 expression than CRCC and PRCC by real-time polymerase chain reaction. Moreover, CHRCC showed higher expression of MR and 11β-HSD2, as compared with OC. Our study indicates MR and 11β-HSD2 are both sensitive and specific markers of the distal nephron and its related neoplasms (CHRCC and OC). Additionally, the staining pattern and the level of MR and 11β-HSD2 expression seems to be useful in the distinction of CHRCC from OC. MR and 11β-HSD2 should be considered in the immunohistochemical panel to more accurately subtype renal cell tumors.

AB - The kidney is an important target for mineralocorticoids. Aldosterone, the major endogenously secreted mineralocorticoid, acts by binding to mineralocorticoid receptor (MR) in the distal renal tubule. The enzyme 11β-hydroxysteroid dehydrogenase type II (11β-HSD2) prevents the binding of glucocorticoids to the MR by inactivating cortisol to cortisone. Our goal was to determine whether MR and 11β-HSD2 expression could be used to characterize the major types of renal cell neoplasms. Using immunohistochemistry we analyzed tissue microarray specimens from 132 patients with renal cell neoplasms, stratified into 84 clear cell renal cell carcinomas (CRCC), including 9 cases clear cell carcinoma with predominantly granular cytoplasm; 14 papillary RCC (PRCC); 20 chromophobe RCC (CHRCC); and 14 oncocytomas (OCs). MR and 11β-HSD2 expression were also quantitated by real-time reverse transcription-polymerase chain reaction. Expression of both MR and 11-βHSD2 was detected in the distal nephrons of normal kidneys. The CHRCC group stained for 11-βHSD2 in a membranous and cytoplasmic pattern whereas diffuse cytoplasmic reactivity was seen in OCs. MR and 11β-HSD2 were coexpressed in most of CHRCC (90% and 95%) and oncocytomas (93% and 100%). No MR staining was detected in CRCC, including clear cell carcinoma with predominantly granular cytoplasm, or in PRCC. Only 2 cases of CRCC (2.6%) showed focal positivity for 11β-HSD2, whereas all PRCCs were negative. CHRCC and OC demonstrated significantly higher levels of MR and 11β-HSD2 expression than CRCC and PRCC by real-time polymerase chain reaction. Moreover, CHRCC showed higher expression of MR and 11β-HSD2, as compared with OC. Our study indicates MR and 11β-HSD2 are both sensitive and specific markers of the distal nephron and its related neoplasms (CHRCC and OC). Additionally, the staining pattern and the level of MR and 11β-HSD2 expression seems to be useful in the distinction of CHRCC from OC. MR and 11β-HSD2 should be considered in the immunohistochemical panel to more accurately subtype renal cell tumors.

KW - 11b-hydroxysteroid dehydrogenase type II

KW - Chromophobe carcinoma

KW - Mineralocorticoid receptor

KW - Oncocytoma

KW - Renal cell neoplasms

UR - http://www.scopus.com/inward/record.url?scp=46249095816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249095816&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e31815f2362

DO - 10.1097/PAS.0b013e31815f2362

M3 - Article

VL - 32

SP - 874

EP - 883

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 6

ER -